|
News Image

Examining the Quality Attributes of NASDAQ:REGN.

By Mill Chart

Last update: Sep 22, 2023

Quality investors are looking for the best of the best. Companies which are growing steadily and consistently, but are also in excellent financial condition. We will have a look here to see if REGENERON PHARMACEUTICALS (NASDAQ:REGN) is suited for quality investing. Investors should of course do their own research, but we spotted REGENERON PHARMACEUTICALS showing up in our Caviar Cruise quality screen, so it may be worth spending some more time on it.

Highlighting Notable Quality Metrics of NASDAQ:REGN.

  • REGENERON PHARMACEUTICALS has demonstrated significant revenue growth over the past 5 years, with a 15.7% increase. This underscores the company's ability to adapt to market dynamics and capitalize on growth opportunities.
  • With a robust ROIC excluding cash and goodwill at 21.99%, REGENERON PHARMACEUTICALS showcases its effective allocation of capital and operational excellence. This metric signifies the company's ability to generate attractive returns and supports its long-term financial performance.
  • The Debt/Free Cash Flow Ratio of REGENERON PHARMACEUTICALS stands at 0.9, reflecting the company's prudent capital structure and cash flow dynamics. This ratio highlights the company's ability to generate robust free cash flow relative to its debt obligations.
  • With a robust Profit Quality (5-year) ratio of 76.98%, REGENERON PHARMACEUTICALS highlights its ability to consistently generate high-quality profits. This metric reflects the company's effective management and operational excellence in delivering reliable earnings over the long term.
  • The 5-year EBIT growth of REGENERON PHARMACEUTICALS has been remarkable, with 19.15% increase. This demonstrates the company's ability to improve its operational efficiency and indicates its competitiveness within the market.
  • With EBIT 5-year growth outpacing its Revenue 5-year growth, REGENERON PHARMACEUTICALS showcases its effective cost management and enhanced operational performance. This suggests the company's ability to generate higher earnings from its revenue streams.

Fundamental Analysis Observations

ChartMill utilizes a proprietary algorithm to assign a Fundamental Rating to every stock. This rating, ranging from 0 to 10, is computed daily by analyzing a variety of fundamental indicators and properties.

Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 615 industry peers in the Biotechnology industry. REGN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. REGN has a decent growth rate and is not valued too expensively.

Our latest full fundamental report of REGN contains the most current fundamental analsysis.

Our Caviar Cruise screen will find you more ideas suited for quality investing.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

REGENERON PHARMACEUTICALS

NASDAQ:REGN (12/8/2023, 7:13:09 PM)

After market: 840.14 0 (0%)

840.14

-9.04 (-1.06%)

REGN News

News Imagea day ago - The Motley FoolCould Regeneron Pharmaceuticals Stock Help You Become a Millionaire?

Regeneron has been an excellent investment in recent years. Can that trend continue?

News Image2 days ago - Regeneron Pharmaceuticals, Inc.Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
News Image2 days ago - Regeneron Pharmaceuticals, Inc.Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

71% objective response rate, with 46% achieving a complete response or better after 11 months of median follow-up Data to be submitted to regulatory...

News Image2 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
News Image2 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO

First dose-escalation results for REGN5668 (MUC16xCD28), a costimulatory bispecific, in combination with Libtayo® (cemiplimab) showed encouraging initial...

News Image3 days ago - Investor's Business DailyRegeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise

Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

News Image5 days ago - The Motley FoolYou Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.

News Image5 days ago - Seeking AlphaEyePoint Pharma stock surges after wet AMD success

EyePoint Pharmaceuticals (EYPT) stock surges as their Phase 2 trial for EYP-1901, a therapy for wet age-related macular degeneration, meets main goals. Read more here.

News Image7 days ago - InvestorPlaceGOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places

The company continues to buy back Alphabet stock in large quantities. As for its other equity investments, it ought to stick with the S&P 500.

News Image8 days ago - ChartmillStay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Friday.

Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

News Image9 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
News Image9 days ago - Regeneron Pharmaceuticals, Inc.Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to...

REGN Links
Follow us for more